Flamel: Near-Term, Under The Radar FDA Catalyst Trade

Flamel: Near-Term, Under The Radar FDA Catalyst Trade While not Coreg CR is a great seller (ie, royalties from Glaxo $ 1.7 million were in 4Q12, wh...


Flamel: Near-Term, Under The Radar FDA Catalyst Trade
While not Coreg CR is a great seller (ie, royalties from Glaxo $ 1.7 million were in 4Q12, which decreased by $ 2.2 million in the same period last year), validated the company’s product drug delivery technology platform and a recent acquisition provides Flamel. ..
Read on
more

Leave a Reply